Bayer announced the initiation of a Phase 2 clinical trial (SIRIUS study) for BAY3018250, the first anti-alpha2 antiplasmin (anti-a2ap) antibody in patients with deep vein thrombosis (DVT).
Pfizer Inc. received marketing approval. Velsipiti (ethrasimod) in the European Union for the treatment of patients with mild to severe ulcerative colitis (UC) did not respond adequately if there is no response to current therapies or biologics.
Global pharmaceutical companies lead the Indian vaccine market with a value share of 60% India's vaccine market is still recovering from the impact of COVID-19, and many nations have regained strength, according to data from research firm Pharm.
Medicines and Healthcare Products UK has updated codeine linctus, an oral solution or syrup licensed for treating dry cough in adults, as a prescription-only treatment due to abuse, dependence and dose magnitude. Will be done
Sun Drug Ventures Ltd said it will acquire a 16.33 percent stake in Surgimatix, Inc, a US-based firm for USD 3.05 million (over Rs 25 crore). Surgimatix is participated occupied with fostering an exclusive delicate tissue obsession gadget for...
WHO Member States continued to discuss proposals to revise the International Health Regulations (HRI, 2005), highlighting the importance of their work for future global security.
The new global business partnership between Boehringer Ingelheim and Slape will expand access to AI to improve the detection, diagnosis and treatment of lameness in horses. This collaboration will enable Boehringer and Sleip to offer innovative
Biocon has announced its inclusion in SandP's 2024 Sustainability Yearbook for the second consecutive year, based on SandP's 2023 Global Corporate Sustainability Assessment (CSA) of Biocon and Biocon Biologics Limited.
Technology advancements, such as continuous blood glucose monitoring (CGM), have made tracking and controlling blood sugar levels easier. This is much needed because access to robust data can help people optimize blood sugar control
The government plans to introduce a new Production Linked Investment (PLI) scheme for the pharmaceutical sector to increase the production of key chemicals to produce active pharmaceutical ingredients (APIs).
, CDSCO.jpg)
